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INTRODUCTION
Prior to 2007, Zika virus (ZIKV) was gen-
erally considered an arbovirus of limited
importance, causing a mild self-limiting
febrile illness in tropical Africa and
Southeast Asia. Now, a large, ongoing out-
break of ZIKV that started in Brazil in
early 2015 is spreading rapidly across the
Americas and has been potentially linked
to congenital malformations (including
microcephaly) and Guillain–Barré syn-
drome (GBS). In England, as of 4
February 2016, ﬁve adults have been diag-
nosed with ZIKV infection following
travel to countries currently experiencing
a ZIKVoutbreak.
ZIKA VIRUS
ZIKV was ﬁrst isolated from a monkey
employed as a sentinel animal in a yellow
fever study in the Zika forest, near
Entebbe, Uganda, in 1947.1 ZIKV is an
RNA arbovirus belonging to the
Flaviviridae family, which also includes
dengue, Japanese encephalitis and West
Nile viruses. The virus is transmitted by
female Aedes mosquitoes, especially, Aedes
aegypti, which is also an effective vector
of dengue and chikungunya virus. Unlike
many other mosquito vectors (eg,
Anopheles spp. that transmit malaria),
Aedes are predominantly day-biting mos-
quitoes. While the majority of human
infections with ZIKV are likely to be
acquired via mosquitoes, the virus has
been detected in semen2 and blood
donors who were asymptomatic at the
time of donation,3 raising the possibility
of sexual transmission and transmission
through blood transfusion, respectively.
CLINICAL DISEASE
Up to 80% of individuals infected with
ZIKV remain asymptomatic and the
remainder usually develop a mild self-
limiting febrile illness lasting 4–7 days
associated with maculopapular rash,
arthralgia, conjunctivitis, itching,
myalgia and headache. The infection is
seldom severe enough to warrant hospi-
talisation and ZIKV-related deaths are
very rarely reported and are mostly asso-
ciated with underlying comorbidities.
Most recently, a teenager with sickle cell
disease in Colombia died after develop-
ing acute respiratory distress syndrome
and hepatic necrosis.4 There is no
vaccine to prevent ZIKV infection and
there are no speciﬁc antiviral treatments
available.
EPIDEMIOLOGY
As ZIKV generally causes such a mild self-
limiting illness, knowledge of its geo-
graphical distribution is dependent mainly
on individual case reports, outbreaks and
seroprevalence studies. Prior to 2007,
reports of ZIKV infection were restricted
to African and Asian countries. The ﬁrst
major outbreak outside the ZIKV natural
territory was reported in 2007 on Yap
Island in Micronesia. In 2013, the virus
spread further east to cause large out-
breaks in French Polynesia with subse-
quent spread to New Caledonia, the Cook
Islands and Easter Island.
In 2015, ZIKV underwent its largest
and fastest geographical expansion. The
ﬁrst autochthonous cases of ZIKV on con-
tinental America were conﬁrmed in north-
eastern Brazil in May 2015 and, since
then, more than 20 countries and territor-
ies in the Americas have reported local
transmission, with the number of affected
countries increasing every week (see
regular Pan American Health
Organization (PAHO) updates for latest
affected countries). A concurrent outbreak
is also currently being reported from
Cape Verde and, occasionally, cases are
diagnosed in travellers returning from
African and Asian countries.
ZIKV AND MICROCEPHALY WITH
CONGENITAL MALFORMATIONS
In October 2015, an unprecedented
increase in cases of infants with micro-
cephaly (box 1), temporally associated
with the emergence of ZIKV, was reported
in the northern Brazilian state of
Pernambuco. Retrospective analysis of the
Brazilian live birth information system
identiﬁed several Brazilian states with sig-
niﬁcant increases in microcephaly com-
pared with previous years. This increase
has continued and, as of 3 February 2016,
4783 cases of microcephaly across Brazil
have been notiﬁed, compared with the
expected 150–200 annual cases (see
Brazilian Ministry of Health for more
information). A large proportion (3670/
4783, 77%) is still under investigation
and awaiting conﬁrmation. So far, 709
(15%) cases have been discarded and, of
the 404 (8%) conﬁrmed with microceph-
aly, 17 (4%) have tested positive for ZIKV.
In a cohort of 35 Brazilian infants with
microcephaly born during August–
October 2015 and reported to the regis-
try, all the mothers lived in or had visited
Box 1 Surveillance case deﬁnition
used by the Brazilian authorities for
congenital microcephaly
▸ Pregnant women with acute
exanthema, and excluded other
known infectious and non-infectious
possible causes
▸ Fetuses with ultrasonographic head
circumference of >2 SDs below the
mean for gestational age, with or
without associated neurological
malformations
▸ Fetuses with ultrasonographic
neurological ﬁndings suggestive of
intrauterine infection
▸ Spontaneous abortions in women
with an exanthem illness without any
identiﬁed cause during pregnancy
▸ Stillbirths at any gestational age in
women with an exanthem illness
without any identiﬁed cause during
pregnancy
▸ Live newborns born prematurely
(<37 weeks gestation) with a head
circumference below the third
percentile
▸ Live term newborns with a head
circumference ≤32 cm
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ZIKV-affected areas during pregnancy, 25
(71%) infants had severe microcephaly
(head circumference >3 SD below the
mean for sex and gestational age), 17
(49%) had at least one neurological
abnormality and all 27 infants who
underwent neuroimaging had abnormal-
ities.5 While the clinical characteristics
and outcomes in these children are only
beginning to be characterised, the current
evidence strongly indicates a causal link
(see European Centre for Disease Control
and Prevention (ECDC) website for
summary). ZIKV appears to share many
similarities to rubella (asymptomatic
infection or mild illness with fever and
rash, but potential for serious birth
defects if infected during pregnancy) but
not with Ebola virus (a severe, haemor-
rhagic infection with a high case fatality
rate, that is transmitted from wild animals
and spread through human-to-human
transmission).
An increase in cases of microcephaly
has yet to be reported from other coun-
tries affected by ZIKV. However, in
November 2015, the French Polynesian
health authorities retrospectively reported
an increase in congenital neurological
malformations in fetuses and newborn
infants from an average of one annual
case to 17 cases during 2014–2015. These
malformations consisted of 12 foetal cere-
bral malformations or multiple congenital
malformations, including brain lesions,
and ﬁve infants with brainstem dysfunc-
tion and absence of swallowing.
Pregnancy was terminated in nine cases.
The remaining infants were born at term
with normal body measurements, but
were found to have multiple malforma-
tions and brain lesions. Common congeni-
tal infections were excluded and further
investigations are ongoing. None of the
mothers reported symptoms of ZIKV
infection during pregnancy. Based on the
temporal correlation of these cases with
the ZIKV outbreaks in French Polynesia,
the local health authorities hypothesise
that ZIKV infection may be associated
with neurological abnormalities if
mothers are infected during the ﬁrst or
second trimester of pregnancy (see ECDC
website for summary).
ZIKV AND GBS
In addition to microcephaly and congeni-
tal malformations, a temporal association
between ZIKV infection and an increase
in cases of GBS is currently being
observed in Brazil, El Salvador and
Venezuela. GBS was also reported follow-
ing the ZIKV outbreak in French
Polynesia.
ZIKV RISK IN THE UK AND EUROPE
ZIKV is likely to continue to spread
across the Americas in the coming
months, with the exception of Canada
and continental Chile, the only countries
in the Americas where Aedes mosquitoes
are not present. A number of European
and other countries have already reported
imported cases of ZIKV. With the continu-
ing spread of the infection in the
Americas, along with increasing awareness
among travellers and clinicians, it is likely
that more cases will be diagnosed and
reported in the coming months in return-
ing travellers. As of 4 February 2016, ﬁve
cases have been diagnosed in the UK in
travellers who have recently returned
from the Americas (see Public Health
England (PHE) website for further
updates). The risk of ZIKV becoming
established in the UK is currently negli-
gible due to a lack of a competent vector.
However, the risk of potential onward
transmission of ZIKV in some southern
European countries where Aedes are
present is a real concern as we move into
the spring and summer months when
mosquito vectors become more active.
IMPLICATIONS FOR TRAVELLERS
As neither treatment nor vaccines are
available, prevention of ZIKV infection
relies on personal protection measures
against mosquito bites, similar to dengue,
chikungunya and other mosquitoborne
infections. Pregnant women and those
trying to become pregnant are advised to
consider avoiding travel to affected areas.
If travel is unavoidable, then strict pre-
ventive measures must be taken to avoid
mosquito bites, both during daytime and
night-time hours (but especially during
mid-morning and late afternoon to dusk,
when the mosquito is most active).
Travellers showing symptoms compatible
with dengue, chikungunya or ZIKV infec-
tion during travel or within 3 weeks of
returning from an affected area should
seek medical advice. Pregnant women
who have travelled to areas with active
ZIKV transmission should mention their
travel history during antenatal visits in
order to be assessed and monitored
appropriately.
IMPLICATION FOR PAEDIATRICIANS
AND NEONATOLOGISTS
1. Paediatricians should be aware of the
mosquito-borne ZIKV outbreak in the
Americas.
2. The vast majority of ZIKV infections
are asymptomatic (80%) or self-
limiting, with most individuals devel-
oping a mild self-limiting febrile illness
lasting 4–7 days associated with macu-
lopapular rash, arthralgia, conjunctiv-
itis, myalgia and headache. However,
ZIKV infection can potentially be
severe in those with underlying
medical conditions.
3. Infection with ZIKV in pregnancy is
potentially associated with microceph-
aly and congenital malformations, par-
ticularly those of the central nervous
system.
4. ZIKV has also been associated with
GBS
5. ZIKV should be considered in the dif-
ferential diagnosis of:
A. any patient with fever returning
from a country where ZIKV out-
breaks are ongoing (see National
Travel Health Network and Centre
(NaTHNaC) website for further
updates);
Useful websites for further information
▸ WHO: http://www.who.int/mediacentre/factsheets/zika/en/
▸ PAHO: http://www.paho.org/hq/index.php?option=com_topics&view=article&id=
427&Itemid=41484
▸ Brazilian Ministry of Health: http://combateaedes.saude.gov.br
▸ ECDC: http://ecdc.europa.eu/en/healthtopics/zika_virus_infection/Pages/index.aspx
▸ US Center for Disease Control and Prevention (CDC): http://www.cdc.gov/zika/
▸ US CDC interim guidance for the evaluation and testing of infants with possible
congenital ZIKV infection: http://www.cdc.gov/mmwr/volumes/65/wr/mm6503e3.
htm#B1_down
▸ Public Health England: https://www.gov.uk/guidance/zika-virus#zika-in-the-uk
▸ NaTHNaC: http://travelhealthpro.org.uk/
▸ Rare and Important Pathogens Laboratory, Public Health England: https://www.
gov.uk/government/collections/rare-and-imported-pathogens-laboratory-ripl
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B. any neurological and autoimmune
syndromes (including GBS) in a
patient who has recently travelled
to a country where ZIKV out-
breaks are ongoing;
C. miscarriage, stillbirth, in-utero death
due to infection, congenital infec-
tion, microcephaly or any other con-
genital (especially neurological)
abnormality in any infant born to a
mother who travelled to a country
where ZIKV outbreaks are ongoing
at any time during pregnancy, even
if the mother was asymptomatic
throughout her pregnancy.
INVESTIGATION AND MANAGEMENT
OF SUSPECTED ZIKV
▸ ZIKV infection can be conﬁrmed by
direct detection of ZIKV RNA or spe-
ciﬁc viral antigens in clinical specimens.
▸ If a case of ZIKV is suspected, clinical
advice and information about
diagnostic testing should be sought in
the ﬁrst instance by contacting the
local virologist, microbiologist or
infectious disease consultant. The
Rare and Imported Pathogens
Laboratory can provide further special-
ist advice as required (https://www.
gov.uk/government/collections/rare-and-
imported-pathogens-laboratory-ripl).
▸ Public Health England advice on
travel, assessment of pregnant women
following travel, advice for those
working in primary care, deferral of
blood donation, information for the
public about ZIKV and media enquiries
are available online (see PHE website
for further updates).
▸ Guidance on the investigation and man-
agement of infants born to mothers
who traveled to a ZIKV endemic
country during pregnancy will shortly
be available on the PHE website.
▸ A British Paediatric Surveillance Unit is
planned to monitor adverse outcomes
in infants born to mothers who trav-
eled to a ZIKV endemic country.
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